Inclusion Criteria:  Patients with stage IV breast cancer Patients with HER2 positive status Patients that received Inetetamab Patients that began Inetetamab therapy prior to June 30, 2021.  Exclusion Criteria:  Patients treated with an investigational anticancer agent Inetetamab